NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis $5.76 +0.06 (+1.05%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.31▼$5.8150-Day Range$3.64▼$6.2752-Week Range$2.57▼$7.00Volume832,998 shsAverage Volume569,609 shsMarket Capitalization$316.56 millionP/E RatioN/ADividend YieldN/APrice Target$12.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get CorMedix alerts: Email Address CorMedix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside118.8% Upside$12.60 Price TargetShort InterestBearish18.78% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.58) to $0.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.01 out of 5 starsMedical Sector769th out of 910 stocksPharmaceutical Preparations Industry359th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCorMedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorMedix has only been the subject of 4 research reports in the past 90 days.Read more about CorMedix's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted18.78% of the outstanding shares of CorMedix have been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 18.9, which indicates bearish sentiment.Change versus previous monthShort interest in CorMedix has recently increased by 1.18%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRMD. Previous Next 3.2 News and Social Media Coverage News SentimentCorMedix has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.Search Interest15 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of CorMedix is held by insiders.Percentage Held by InstitutionsOnly 34.18% of the stock of CorMedix is held by institutions.Read more about CorMedix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CorMedix are expected to grow in the coming year, from ($0.58) to $0.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is -6.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is -6.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 6.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CorMedix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” About CorMedix Stock (NASDAQ:CRMD)CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Read More CRMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRMD Stock News HeadlinesAugust 28, 2024 | uk.finance.yahoo.comCormedix Inc (19KA.SG)August 28, 2024 | americanbankingnews.comRodman & Renshaw Initiates Coverage on CorMedix (NASDAQ:CRMD)September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 27, 2024 | msn.comRodman & Renshaw Initiates Coverage of CorMedix (CRMD) with Buy RecommendationAugust 19, 2024 | finance.yahoo.comCVAC Sep 2024 2.000 call (CVAC240920C00002000)August 18, 2024 | ca.finance.yahoo.comCRMD Sep 2024 8.000 putAugust 17, 2024 | ca.finance.yahoo.comCRMD Sep 2024 11.000 callAugust 17, 2024 | ca.finance.yahoo.comCRMD Mar 2025 3.000 putSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 17, 2024 | ca.finance.yahoo.comCRMD Mar 2025 5.000 callAugust 17, 2024 | ca.finance.yahoo.comCRMD Mar 2025 7.000 callAugust 17, 2024 | ca.finance.yahoo.comCRMD Mar 2025 4.000 putAugust 17, 2024 | ca.finance.yahoo.comCRMD Mar 2025 6.000 callAugust 15, 2024 | msn.comCorMedix Inc. (NASDAQ:CRMD) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | finance.yahoo.comWe Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business GrowthAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed: Promising DefenCath Launch and Financial Stability Position Cormedix for Market GrowthAugust 14, 2024 | msn.comCorMedix (CRMD) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comCorMedix Inc. (CRMD) Q2 2024 Earnings Call TranscriptSee More Headlines Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRMD CUSIPN/A CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$12.60 High Stock Price Target$19.00 Low Stock Price Target$9.00 Potential Upside/Downside+118.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,340,000.00 Net MarginsN/A Pretax Margin-6,763.03% Return on Equity-82.50% Return on Assets-71.00% Debt Debt-to-Equity RatioN/A Current Ratio4.79 Quick Ratio4.43 Sales & Book Value Annual Sales$806,119.00 Price / Sales392.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book6.94Miscellaneous Outstanding Shares54,959,000Free Float52,980,000Market Cap$316.56 million OptionableOptionable Beta1.59 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Joseph Todisco MBA (Age 47)CEO & Director Comp: $1.07MDr. Matthew T. David M.D. (Age 45)Executive VP & CFO Comp: $597.27kMs. Erin Mistry (Age 41)Executive VP & Chief Commercial Officer Comp: $561.57kMs. Elizabeth Masson-Hurlburt B.A. (Age 44)Executive VP and Chief Clinical Strategy & Operations Officer Comp: $538.91kMs. Kaufman Beth Zelnick Esq.Executive VP, Chief Legal Officer & Corporate SecretaryDonna UcciSenior VP & Head of Global QualityDr. Tushar MukherjeeSenior VP & Head of Technical OperationsMore ExecutivesKey CompetitorsBlack Diamond TherapeuticsNASDAQ:BDTXSolid BiosciencesNASDAQ:SLDBNeoleukin TherapeuticsNASDAQ:NLTXAquestive TherapeuticsNASDAQ:AQSTNature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 31,893 shares on 9/5/2024Ownership: 0.058%The Manufacturers Life Insurance Company Bought 2,700 shares on 8/15/2024Ownership: 0.042%AQR Capital Management LLCSold 12,641 shares on 8/15/2024Ownership: 0.020%Marshall Wace LLPBought 79,619 shares on 8/14/2024Ownership: 0.277%Renaissance Technologies LLCSold 77,925 shares on 8/9/2024Ownership: 0.292%View All Insider TransactionsView All Institutional Transactions CRMD Stock Analysis - Frequently Asked Questions How have CRMD shares performed this year? CorMedix's stock was trading at $3.76 on January 1st, 2024. Since then, CRMD shares have increased by 53.2% and is now trading at $5.76. View the best growth stocks for 2024 here. How were CorMedix's earnings last quarter? CorMedix Inc. (NASDAQ:CRMD) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business earned $0.81 million during the quarter, compared to analysts' expectations of $0.75 million. When did CorMedix's stock split? CorMedix's stock reverse split before market open on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Who are CorMedix's major shareholders? CorMedix's top institutional investors include Renaissance Technologies LLC (0.29%), Bank of New York Mellon Corp (0.29%), Marshall Wace LLP (0.28%) and Commonwealth Equity Services LLC (0.17%). Insiders that own company stock include Myron Kaplan and Matthew T David. View institutional ownership trends. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV) and QUALCOMM (QCOM). This page (NASDAQ:CRMD) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.